Metropolis Healthcare Limited

Metropolis Healthcare's Q4FY26 revenue grew 23% YoY, driven by strong B2B (30% growth) and B2C (19% growth) channels. Recent acquisitions (Core Diagnostics, DAPIC, etc.) are integrated, with Core Diag

Metropolis Healthcare allotted 15,54,95,826 bonus equity shares on March 23, 2026, in a 3:1 ratio. Post-allotment paid-up share capital increased to ₹41,46,55,536 comprising 20,73,27,768 equity shares